Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
AstraZeneca
Baxter
Johnson and Johnson
Moodys

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,214,506

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,214,506 protect, and when does it expire?

Patent 7,214,506 protects JUBLIA and is included in one NDA.

This patent has thirteen patent family members in eleven countries.

Summary for Patent: 7,214,506
Title:Method for treating onychomycosis
Abstract: A novel method for evaluating an effect of an antimicrobial agent which comprises removing the antimicrobial agent remaining in a biological sample or the like to thereby accurately evaluate the effect of the antimicrobial agent without being affected by the remaining antimicrobial agent. A therapeutic agent for onychomycosis which can be obtained according to the evaluation method of the drug effect.
Inventor(s): Tatsumi; Yoshiyuki (Otsu, JP), Yokoo; Mamoru (Otsu, JP), Nakamura; Kosho (Moriyama, JP), Arika; Tadashi (Suita, JP)
Assignee: Kaken Pharmaceutical Co., Ltd. (Bunkyo-ku, Tokyo, JP)
Application Number:10/685,266
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,214,506
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,214,506

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes   Start Trial   Start Trial ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,214,506

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan11/214369Jul 28, 1999

International Family Members for US Patent 7,214,506

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 434667   Start Trial
Australia 5852400   Start Trial
Canada 2391274   Start Trial
Cyprus 1109281   Start Trial
Germany 60042453   Start Trial
Denmark 1205559   Start Trial
European Patent Office 1205559   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
AstraZeneca
Mallinckrodt
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.